Fasken handed cancer drug licensing deal
Fasken Martineau Stringer Saul has represented longstanding client Antisoma on a global licensing agreement with pharmaceutical firm Novartis. The deal concerns Antisoma’s vascular disruption drug AS1404, which is in development for the treatment of lung, ovarian and prostate cancers. If all requirements are met Antisoma could receive up to $890m (£446.91m) in addition to royalties […]